AC Immune SA
F:IMR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AC Immune SA
F:IMR
|
CH |
AC Immune SA
AC Immune SA is a Swiss biotechnology company focused on diseases of the brain, especially Alzheimer’s and Parkinson’s disease. It discovers and develops medicines and diagnostic tools aimed at the abnormal proteins that build up in these disorders, such as amyloid-beta, tau, and alpha-synuclein. Its work is still largely in the research and clinical-development stage, so it is not a mass-market drug seller; it is a company trying to turn scientific discoveries into therapies and tests that can be approved and commercialized. The company makes money mainly through research partnerships, licensing deals, and milestone payments from larger drug companies that help fund development or take over later-stage commercialization. It also works on its own drug candidates and diagnostic programs, which could generate future product revenue if they reach the market. Its main customers and partners are pharmaceutical companies, research collaborators, and, ultimately, doctors and patients if its programs succeed. What makes AC Immune different is its narrow focus on the biology of neurodegenerative disease and on disease-modifying approaches rather than symptom relief. It sits at the front end of the drug pipeline, where success depends on strong scientific validation, clinical data, and partnerships with bigger industry players that can finance expensive late-stage development and commercialization.
AC Immune SA is a Swiss biotechnology company focused on diseases of the brain, especially Alzheimer’s and Parkinson’s disease. It discovers and develops medicines and diagnostic tools aimed at the abnormal proteins that build up in these disorders, such as amyloid-beta, tau, and alpha-synuclein. Its work is still largely in the research and clinical-development stage, so it is not a mass-market drug seller; it is a company trying to turn scientific discoveries into therapies and tests that can be approved and commercialized.
The company makes money mainly through research partnerships, licensing deals, and milestone payments from larger drug companies that help fund development or take over later-stage commercialization. It also works on its own drug candidates and diagnostic programs, which could generate future product revenue if they reach the market. Its main customers and partners are pharmaceutical companies, research collaborators, and, ultimately, doctors and patients if its programs succeed.
What makes AC Immune different is its narrow focus on the biology of neurodegenerative disease and on disease-modifying approaches rather than symptom relief. It sits at the front end of the drug pipeline, where success depends on strong scientific validation, clinical data, and partnerships with bigger industry players that can finance expensive late-stage development and commercialization.
